US FDA declines to approve Camurus rare hormone disorder drug - Reuters
| CAMX Stock | SEK 559.50 10.50 1.84% |
Slightly above 67% of Camurus AB's investor base is looking to short. The analysis of current outlook of investing in Camurus AB suggests that many traders are alarmed regarding Camurus AB's prospects. Camurus AB's investing sentiment can be driven by a variety of factors including economic data, Camurus AB's earnings reports, geopolitical events, and overall market trends.
Camurus |
US FDA declines to approve Camurus rare hormone disorder drug Reuters
Read at news.google.com
 |
Camurus AB Fundamental Analysis
We analyze Camurus AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Camurus AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Camurus AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Camurus AB is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Camurus AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Camurus AB stock to make a market-neutral strategy. Peer analysis of Camurus AB could also be used in its relative valuation, which is a method of valuing Camurus AB by comparing valuation metrics with similar companies.
Peers
Camurus AB Related Equities
| BIOA-B | BioArctic | 2.80 | ||||
| SOBI | Swedish Orphan | 0.87 | ||||
| ONCO | Oncopeptides | 0.67 | ||||
| HNSA | Hansa Biopharma | 1.59 |
Additional Tools for Camurus Stock Analysis
When running Camurus AB's price analysis, check to measure Camurus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Camurus AB is operating at the current time. Most of Camurus AB's value examination focuses on studying past and present price action to predict the probability of Camurus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Camurus AB's price. Additionally, you may evaluate how the addition of Camurus AB to your portfolios can decrease your overall portfolio volatility.